With regard to drug safety in Canada and the protection of Canadians’ health: (a) for each of the recommendations in the Auditor General’s 2011 fall report, Chapter 4, Regulating Pharmaceutical Drugs—Health Canada, what are the actions taken to date, and specifically, which of these actions (i) has yet to begin, (ii) is in progress, (iii) is completed; (b) for drugs produced in off-shore factories, how does Health Canada monitor safety, (i) how many inspections has it undertaken since 2006, and (ii) for each identified inspection, what was the reason for investigating, and what were the results; (c) what are all the positive and negative impacts of the “user-fee” model, by which drug companies pay to submit a drug for approval, and what, if any, research or investment has been undertaken to consider alternative models, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (d) will Health Canada make registering clinical trials for drugs mandatory, and if so, when; (e) what, if any, research or investment has been undertaken to examine whether the pharmaceutical industry suppresses negative clinical trial results, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (f) what, if any, research or investment has been given to having Health Canada provide information regarding clinical trials, including, but not limited to, information confirming safety and efficacy, the number of people in the trials, and the number of people who drop out due to bad side effects, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (g) what, if any, research or investment has been undertaken to identify new drugs for consumers, as in the United Kingdom, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (h) what, if any, research or investment has been undertaken to adopt plain language labelling, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (i) will Health Canada be undertaking plain language labelling and, if so, when; (j) what specific post-market monitoring of drugs does Health Canada undertake itself, (i) how many drugs have been approved since 2006, (ii) how many of these were later given safety warnings, (iii) how many of these were later removed from market, (iv) for each drug given a warning or a removal, did it follow a warning or removal by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA), (v) did Health Canada ever issue a warning or removal before the EMA/FDA; (k) what specific post-market monitoring of drugs that have had a 180-day priority review does Health Canada undertake itself, (i) how many drugs have been approved since 2006, (ii) how many were later given safety warnings, (iii) how many of these were later removed from market, (iv) for each drug given a warning or a removal, did it follow a warning or removal by the EMA or the FDA, (v) did Health Canada ever issue a warning or removal before the EMA/FDA; (l) when will Health Canada offer a list of drugs that received fast-track approval, and why fast-tracking took place, (ii) what other variables might Health Canada consider making available to increase transparency regarding priority-review drugs; (m) what, if any, research or investment has been undertaken to develop an independent drug-monitoring agency with the power to remove unsafe drugs from the market, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (n) what, if any, research or investment has been undertaken to provide plainly worded risk warnings, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; (o) will Health Canada be undertaking plainly-worded risk warnings, and if so, when; (p) how many Canadians die each year of prescription drugs in Canada, (i) what is the most recent data Health Canada has regarding these deaths, (ii) what specific action has Health Canada taken to reduce these numbers, (iii) what data does Health Canada or the Canadian Institutes for Health Research have regarding how these data are expected or predicted to change in the future; (q) what action has been taken to address each of the 59 recommendations of the coroner’s jury in the inquiry into Ms. Vanessa Young's death, what action has been taken to address each of the 16 recommendations of the coroner’s jury in the inquiry into Ms. Sara Carlin's death, and for each recommendation, (i) is the recommendation being acted upon, in progress, or completed, (ii) if it is not being acted upon, why; (r) what, if any, research or investment has been undertaken to making “related to a drug prescribed” a category of death, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (s) what, if any, research or investment has been undertaken to determine what percentage of adverse reactions are never reported, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (t) what, if any, research or investment has been undertaken to make reporting adverse effects of drugs mandatory for doctors, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; (u) what, if any, research, or investment has been undertaken to make reporting adverse effects of drugs mandatory for pharmacists, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (v) what, if any, research or investment has been undertaken to make reporting adverse effects of drugs mandatory for all healthcare professionals, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (w) what, if any, research or investment has been undertaken to make public adverse effects reports from companies, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (x) what, if any, research or investment has been undertaken to make Health Canada’s on-line, adverse-reactions-to-drugs database more navigable and user-friendly, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (y) when will Health Canada offer a full list of every warning given for a specific drug; (z) what, if any, research or investment has been undertaken to make Health Canada’s website more user-friendly and transparent, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; and (aa) what, if any, research or investment has been undertaken to give Health Canada the authority to unilaterally revise a label or remove a drug from market, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when?